Abstract 645P
Background
MEK inhibition (MEKi) may act synergistically when combined with cytotoxics in RAS mutated (mt) metastatic colorectal tumours (mCRC). We investigated the safety and clinical activity of MEKi, binimetinib, and mFOLFIRI in patients (pts) with RAS mt mCRC.
Methods
Eligibility criteria: Pts >18 years with RAS mt mCRC, ECOG 0-1, acceptable organ function, measurable disease, and progression or ineligibility to oxaliplatin. Pts received binimetinib plus mFOLFIRI, in a dose-escalated standard 3+3 design, to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). A 6-day lead-in period with binimetinib alone was required prior to combination therapy. Two levels of binimetinib were evaluated - 30mg BID and 45mg BID - and given on days 1-12/14-day cycle po with mFOLFIRI every 14 days iv. An additional 12 patients enrolled in the dose expansion phase to assess preliminary efficacy. The study completed accrual and herein we report the updated results.
Results
13 pts enrolled in the dose escalation phase (7 pts on the first binimetinib dose level and 6 on the second) and 12 pts in the expansion phase. Median age was 49 yrs (35-71), and 13 were male. All pts in expansion and 9 in escalation, had received irinotecan prior. All pts in the expansion cohort had irinotecan refractory disease. The MTD of binimetinib was 45mg BID. The most common grade 1-2 adverse effects (AEs) (%) were diarrhoea (64), fatigue (64), nausea (48), vomiting (44), rash (24). Grade 3-4 AEs included fatigue (12), rash (4), heart failure (4), and pneumonitis (4). 1 pt with pre-existing heart disease had a DLT of decreased cardiac ejection fraction on dose level 1. 17 pts discontinued therapy due to progression, 5 due to AEs and 3 for other reasons. The mean number of FOLFIRI and MEK cycles received was 6.7 (0-29) and 7.5 (1-30), respectively. Of the 25 pts, 24 were evaluable for response. Best response included 1 PR and 12 SD (all had received prior irinotecan and 10 had progressed on it). 4 pts remained on study for >6 months (7-15). The median PFS was 3.35 months (95% CI 2-8.61) and the median OS was 8.41 months (95% CI 4.7-12.8).
Conclusions
MEKi plus mFOLFIRI has acceptable toxicity and showed activity even in patients with prior progression on irinotecan.
Clinical trial identification
NCT02613650.
Editorial acknowledgement
Legal entity responsible for the study
Huntsman Cancer Institute.
Funding
Huntsman Cancer Institute, Pfizer.
Disclosure
V. Florou: Financial Interests, Personal, Advisory Role: Deciphera, Incyte. H.P. Soares: Financial Interests, Personal, Advisory Board: TerSera, Ipsen, AstraZeneca, Novartis, ITM. I. Garrido-Laguna: Financial Interests, Personal, Advisory Role: SOTIO, Kanaph, Jazz, OncXerna. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11